Quality Management Review Meeting Record

This is a ready-to-use management review record. It is the document a periodic management review is captured on, and it pairs with your quality management system governance procedure. Replace every <<FILL: ...>> placeholder with your own specifics, set your own document numbers, meeting dates, and review period, and route the completed record through your normal document control, review, and approval. Populate the fields as the meeting runs, not all afterward, so the minutes reflect what was actually discussed and decided. A worked filled specimen of a quarterly review follows the template so you can see how a completed record reads. Verify each cited regulation against the current source before you rely on it. Using this template does not by itself create compliance; the review must actually happen, the data must be real, and the actions must be tracked to closure.

Document control header

1. Purpose of this record

This record captures a management review of the quality system at <<FILL: COMPANY / SITE NAME>> for the period stated in the header. Management review is the mechanism by which senior management examines the performance and suitability of the quality system, makes decisions on it, commits resources, and escalates risk. The record exists to show that the review happened, what data was examined, what was decided, who owns each action, and when each action is due. It is the standing evidence an inspector asks for when they want to see that senior management is engaged in quality, not just the quality unit.

2. Attendance and quorum

Record everyone present, their role, and whether they attended in person or remotely. A management review is only meaningful if the people who can commit resources and direct the organization are in the room, so identify senior management attendance explicitly. State the quorum rule from your procedure and confirm it was met.

3. Roles and responsibilities

4. Standing agenda and inputs

Each numbered item below is a standing input. For every item, record the data presented, the trend (improving, stable, or deteriorating versus the previous period), and any conclusion or action. Reference the source report rather than repeating its detail, so the record stays readable and the underlying data stays traceable.

4.1 Actions from the previous review

State plainly whether any prior action is overdue and what is being done about it. Repeatedly overdue actions are themselves a signal that the review process is not effective.

4.2 Quality metrics and trends

Summarize the period’s quality metrics against their targets and against the prior period. Reference the metrics report by number.

Source report: <<FILL: metrics report number / date>>.

4.3 Deviation and CAPA status

Report the volume, aging, and trend of deviations and CAPAs. Call out recurring or systemic issues, repeat root causes, and any backlog.

4.4 Complaints, recalls, and field actions

4.5 Audit and inspection outcomes

Summarize internal audits, supplier audits, and regulatory inspections in the period, with finding counts and the status of any commitments.

Note any open regulatory commitments and whether they are on track.

4.6 Change control status

4.7 Supplier and contract partner performance

4.8 Training and personnel competence

State training completion against plan, any gaps tied to GxP roles, and any competence concerns raised by deviations or audits.

4.9 Regulatory commitments and changes in the regulatory environment

Record the status of commitments made to health authorities and any new or revised regulations that affect the operation, with the planned response.

4.10 Resource adequacy

State whether staffing, facilities, equipment, and systems are sufficient to maintain the quality system, and record any resource request and the decision on it. This is where the review either commits resources or accepts a documented risk.

4.11 Status of the pharmaceutical quality system itself

Record any other input bearing on the suitability of the quality system: outcomes of product quality reviews, process performance and product quality monitoring, stability program signals, validation status, and the state of continual improvement initiatives.

5. Risk escalation to senior management

List the risks raised to senior management at this review, the decision taken, and the owner. This is the part of the record that shows risk reached the people who can act on it and that they did act.

6. Decisions and conclusions

Record the decisions reached, including the overall management conclusion on whether the quality system remains suitable, adequate, and effective for the period under review.

Overall management conclusion on quality system suitability and effectiveness: <<FILL: statement>>.

7. Actions arising

Every action gets a unique ID, a single named owner, and a due date. Vague owners (“Quality”) and missing due dates are the two failures inspectors look for here.

All actions are logged in the action tracker <<FILL: reference>> and reviewed at the next management review.

8. Approvals

9. Revision history

Filled specimen

The following shows the same record completed for a fictional quarterly review at “Acme Bio”, Site B, a sterile biologics fill-finish operation. The company, people, systems, and numbers are illustrative; replace them with your own.

Header

Attendance and quorum

Quorum required: Site Head plus Head of Quality plus three function heads. Quorum met: Yes. Chair: M. Alvarez. Minute taker: J. Okafor (delegate, QA).

Selected inputs

Actions from previous review: 6 prior actions; 5 closed, 1 overdue. Overdue action ACT-2025-Q4-03 (qualify second sterile filter supplier) re-baselined with a firm date and escalated to the risk register (see below).

Quality metrics: batch acceptance 99.1% (prior 98.4%, target 98%, improving). On-time deviation closure 84% (prior 79%, target 90%, improving but below target). On-time CAPA closure 91% (prior 88%, target 90%, on target). Confirmed OOS 0.4% (stable). Complaint rate 0.6 per million units (prior 0.9, improving). Source: metrics report MET-2026-Q1.

Deviations and CAPA: 38 deviations opened (prior 45), 41 closed; 3 aged beyond the 30-day target; 1 major (an aseptic process simulation with one contaminated unit, handled as a failed run with full investigation and line revalidation); 0 critical. Recurring root cause: operator aseptic technique flagged in 2 deviations, addressed by the retraining action below.

Complaints, recalls, field actions: 14 complaints, 4 confirmed (cosmetic vial defects); 0 recalls; 1 Field Alert Report filed under 21 CFR 314.81 for a suspected stability trend, within 3 working days; 0 Biological Product Deviation Reports.

Audit and inspection: 1 internal audit (QC laboratory, 0 critical, 2 major, 5 minor, all with CAPAs on track); 1 supplier audit (primary container supplier, acceptable); no regulatory inspection this quarter. Open commitment from the prior FDA inspection (audit-trail review SOP rollout) on track for Q2.

Change control: 22 changes opened, 19 closed, 1 overdue; 1 significant change (new lyophilizer cycle) progressing under its validation plan.

Supplier performance: sterile filter sole-source remains the standing risk; second-supplier qualification behind schedule. Container supplier performance acceptable.

Training: curriculum completion 96% against a 98% target; 4 GxP-role staff overdue, action assigned to close by 30 April 2026.

Regulatory commitments and environment: the team noted the QMSR effective date of 2 February 2026 and the FDA Computer Software Assurance guidance (current version issued 3 February 2026); IT Quality to assess the impact on the validation approach next quarter.

Resource adequacy: staffing adequate; QC requested one additional analyst to protect deviation closure timeliness; approved. Validation capacity flagged as tight given the CSA reassessment; held for decision pending the Q2 impact assessment.

Risk escalation to senior management

Decisions and conclusions

The quality system is judged suitable, adequate, and effective for the period, with two areas requiring management attention: deviation closure timeliness (improving but below target) and single-source sterile filter risk. One additional QC analyst approved. Second sterile filter qualification funded and escalated.

Actions arising

Approvals

Prepared by: J. Okafor (QA), signed 16 April 2026. Reviewed by: M. Alvarez (Site Head), signed 17 April 2026. Approved by: J. Okafor (Head of Quality), signed 17 April 2026.

In this example the review did three things an inspector wants to see: it examined real performance data against targets and the prior quarter, it pushed a genuine supply risk up to the person who could fund the fix, and it produced actions with named single owners and firm due dates, each tracked to the next review.

Common inspection findings this record prevents

• Management review is required by procedure but no record shows senior management actually attended or decided anything.
• The minutes list topics discussed but contain no decisions, owners, or due dates.
• Actions are assigned to a department, not a named person, and have no due date.
• Prior-review actions are carried over quarter after quarter with no closure and no escalation.
• Risks are noted in the body but never escalated to or acted on by senior management.
• The review records metrics but shows no trend versus prior periods and no conclusion on whether the quality system is effective.

How to adapt this record

1. Set your document number, owner, governing procedure, and review frequency in the header.
2. Align the standing agenda in section 4 with the inputs your QMS governance procedure requires, and add any local inputs (for example product quality review outputs or process monitoring) you track.
3. Reference your real metrics, deviation, CAPA, complaint, audit, change, supplier, and training reports rather than repeating their content here.
4. Confirm your quorum rule and senior-management attendance requirement match your procedure.
5. Log every action into your action tracker the same day and review the prior actions first at the next meeting.
6. Confirm every regulation in the next section against the current published version before issue.

Regulations this supports

• ICH Q10, Pharmaceutical Quality System (management review and management responsibilities).
• ICH Q9(R1) (2022), Quality Risk Management, FDA-adopted 2023 (risk-based decisions and escalation).
• EU GMP Chapter 1, Pharmaceutical Quality System (management responsibilities and review).
• EU GMP Annex 1 (2022) where sterile operations are in scope (contamination control strategy outputs as a review input).
• 21 CFR 211, Current Good Manufacturing Practice for Finished Pharmaceuticals (quality unit responsibilities and oversight).
• 21 CFR 314.81, Field Alert Report (filed within 3 working days).
• 21 CFR 600.14, Biological Product Deviation Report (filed within 45 calendar days).
• 21 CFR 820 harmonized with ISO 13485 (QMSR), effective 2 February 2026, where combination products are in scope (management review as a quality system input).